Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Revenue (2023)

Contineum Therapeutics' Revenue history spans 1 years, with the latest figure at $50.0 million for Q2 2023.

  • Quarterly Revenue changed N/A to $50.0 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $50.0 million through Jun 2024, changed N/A year-over-year, with the annual reading at $50.0 million for FY2023, N/A changed from the prior year.
  • Revenue came in at $50.0 million for Q2 2023.
  • In the past five years, Revenue ranged from a high of $50.0 million in Q2 2023 to a low of $50.0 million in Q2 2023.